Zydus Lifesciences Incorporates Wholly Owned US Subsidiary Zara Merger SUB Inc.

Zydus Lifesciences has incorporated a wholly owned subsidiary in the United States named Zara Merger SUB Inc. on April 24, 2026. The company received information about the incorporation on April 29, 2026, and filed the intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 on April 30, 2026.

Subsidiary Details

Zara Merger SUB Inc. is authorized to issue 1,000 common stock with a par value of USD 0.001 per share. The subsidiary has nil turnover as it is yet to commence business operations. The incorporation is not a related party transaction, and the Promoter, Promoter Group, or Group Companies have no interest in the said incorporation.

Particulars	Details
Name of Entity	Zara Merger SUB Inc.
Authorized Capital	1,000 common stock
Par Value	USD 0.001 per share
Turnover	Nil
Shareholding	100%
Industry	Pharmaceutical

Strategic Purpose

The incorporation of Zara Merger SUB Inc. is intended for internal group restructuring. The consideration for 100% subscription to the paid-up share capital of Zara is in cash. No governmental or regulatory approvals are required as this intimation concerns a newly incorporated wholly owned subsidiary.

Market Expansion

This development represents Zydus Lifesciences 's continued focus on strengthening its presence in the United States pharmaceutical sector. The formation of this new subsidiary aligns with the company's broader international growth strategy and operational framework enhancement in the American market.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-2.08%	-4.09%	-0.54%	-11.07%	+0.43%	+58.84%

Zydus Lifesciences has received approval from the Drug Controller General of India (DCGI) to initiate two Phase III clinical trials for Zintrodiazine, a novel anti-malarial candidate active against all current clinical strains of Plasmodium falciparum and Plasmodium vivax, including drug-resistant strains. The announcement was made through a press release dated April 25, 2026.

Clinical Trial Details

The company will conduct two multi-centre, randomised, assessor-blind, active-comparator studies to evaluate the efficacy, safety and tolerability of orally administered Zintrodiazine. The first Phase III trial will involve 651 patients with uncomplicated malaria due to P. falciparum, while the second trial will enroll 390 patients with uncomplicated P. vivax malaria. Both trials will use PCR-adjusted adequate clinical and parasitological response (ACPR) as the primary efficacy endpoint.

Trial Parameter	P. falciparum Study	P. vivax Study
Patient Count	651	390
Study Type	Multi-centre, randomised, assessor-blind, active-comparator	Multi-centre, randomised, assessor-blind, active-comparator
Primary Endpoint	PCR-adjusted ACPR	PCR-adjusted ACPR

Secondary endpoints in both trials will include the incidence of recrudescence, new infections, parasite clearance time and fever clearance time.

Strategic Context and Collaboration

Last year, over 1,80,000 people were diagnosed with malaria in India. In 2016, Medicines for Malaria Venture (MMV) and Zydus announced a collaboration to develop a Zintrodiazine-containing drug combination as an effective alternative to current artemisinin-based combination therapies (ACTs), which face increasing resistance threats. The WHO's World Malaria Report 2025 notes that partial resistance to artemisinin derivatives has been confirmed or suspected in at least 8 countries in Africa.

Company Perspective

Dr. Sharvil Patel, Managing Director of Zydus Lifesciences Limited, stated that the approval marks a critical milestone in the fight against malaria. He emphasized the company's commitment to developing effective treatments to address the challenge of increasing resistance to current therapies. Zydus Lifesciences employs over 29,000 people worldwide, including 1,500 scientists engaged in research and development.